Joseph Zanghi, DO
Urology · Olympia Fields, ILNPI 1013371442
Payments from drug & device makers
Across 185 payments — averaging $47.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$4K
- Boston Scientific$530
- Procept Biorobotics Corporation$524
- Coloplast$492
- Medtronic$432
- Olympus America Inc.$384
- plus $2K from 35 others
What the payments were for
- Travel & lodging$1,72320%
- Food & beverage$7,10480%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 42 | $4,090 |
| Boston Scientific | 8 | $530 |
| Procept Biorobotics Corporation | 8 | $524 |
| Coloplast | 10 | $492 |
| Medtronic | 13 | $432 |
| Olympus America Inc. | 9 | $384 |
| Teleflex LLC | 6 | $299 |
| Dendreon Pharmaceuticals LLC | 8 | $185 |
| Antares Pharma, Inc. | 11 | $174 |
| KARL Storz Endoscopy-america | 1 | $150 |
| Conmed Corporation | 1 | $138 |
| Laborie Medical Technologies Corp. | 2 | $125 |
| SRS Medical Systems, Inc. | 1 | $118 |
| AbbVie | 7 | $103 |
| Convatec Inc. | 5 | $99 |
| Myovant Sciences Inc. | 4 | $90 |
| Bayer | 4 | $86 |
| Astellas Pharma US Inc | 5 | $81 |
| Progenics Pharmaceuticals, Inc. | 4 | $74 |
| Merck | 5 | $73 |
| Telix Pharmaceuticals | 2 | $64 |
| Tempus AI, Inc | 2 | $45 |
| Cook Medical LLC | 2 | $45 |
| Blue Earth Diagnostics | 2 | $43 |
| Pfizer | 3 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $37 |
| Accord Healthcare, Inc. | 2 | $34 |
| Urogen Pharma, Inc. | 2 | $32 |
| Immunitybio, Inc. | 2 | $31 |
| 180 Medical, Inc. | 1 | $21 |
| Davol Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Pelvital USA, Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Calyxo, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$2,892
- Bulkamid$1,801
- iTIND System$263
- HOPKINS$150
- UroLift$149
- Luja Coude$142
- AIRSEAL$138
- INTERSTIM$130
- GENERAL KIDNEY STONE DISEASE$122
- UroCuff$118
- Pyelostent$108
- Porges Coloplast$107
How this compares
$8,827 in reported general payments places this provider in the 75th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 221 | $147,413 |
| MyrbetriqMirabegron | 198 | $113,023 |
| Abiraterone Acetate | 35 | $67,411 |
| Mirabegron ErMirabegron | 23 | $11,058 |
| Tamsulosin Hcl | 570 | $9,277 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 96 | $4,349 |
| Estradiol | 60 | $4,160 |
| Silodosin | 13 | $2,500 |
| Methenamine Hippurate | 19 | $1,858 |
| Oxybutynin Chloride ErOxybutynin Chloride | 77 | $1,797 |
| NitrofurantoinNitrofurantoin Macrocrystal | 31 | $1,347 |
| Finasteride | 99 | $1,174 |
| Solifenacin Succinate | 36 | $816 |
| Oxybutynin Chloride | 105 | $571 |
| Tadalafil | 19 | $519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $147,413221 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $113,023198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 urology providers in Illinois.
Other urology in Olympia Fields
- James SiegertOlympia Fields$37K
- Mark BrandtPark Ridge$3M
- Ashley RossChicago$2.3M
- Aaron BergerChicago Ridge$2.1M
- Joshua MeeksChicago$2M
- Courtney HollowellChicago$1.9M
- David LieberSpringfield$1.5M
- Gary SteinbergChicago$1.4M
- Brian HelfandChicago$1.2M
- Simone CrivellaroChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.